CML Insight, Inc.
  • Platform
  • Research
  • Team
  • Careers
Book a working session
CML Insight, Inc.
Book a sessionBook a working session
CML Insight Logo

CML Insight, Inc.

Austin, Texas

United States (English)

Follow us

Industries

  • Higher Education
  • K12 Education
  • Healthcare
  • Water Utilities
  • Fintech
  • Social Impact
  • Compare industries

Company

  • Team
  • Careers
  • Research
  • Security
  • Request a demo
  • Contact

Resources

  • Privacy Policy
  • Terms of Service
  • Sitemap
  • Accessibility

Contact

info@cmlinsight.com

© 2026 CML Insight, Inc. All rights reserved.

PrivacyTerms
C(t) = D/V·e^(-k·t)AUC = ∫C(t)dtt½ = 0.693/k5'-ATCGATCG-3'3'-TAGCTAGC-5'HR = 0.72 (95% CI: 0.58-0.89)p < 0.001NNT = 1/ARROR = (a/c)/(b/d)RR = P(D|E)/P(D|¬E)Css = F·D/(τ·CL)λ = -ln(S(t))/tE = Emax·C/(EC50 + C)dC/dt = -k·C⦾⦾
  1. Home
  2. Industries
  3. Healthcare

Understand why patient trajectories unfold, and what would change them

For pharmaceutical innovators, providers and payers: causal inference on high-frequency ICU data and longitudinal claims, digital twins that simulate treatment policies, and agents that explain results with the trial evidence beside them.
Book a working sessionSee the ICU simulator
IllustrativeSame patients, two policiesICU mortalitytreatment withheldpolicy (counterfactual)ICU day 0day 7

Healthcare partners we work with

  • Mcure Biosciences
  • Vayu
Capabilities

From correlation to cause, at the bedside and across populations

Causal inference

Cause-and-effect in treatment pathways, with doubly robust checks and positivity diagnostics.

Time-series expertise

Architectures for high-frequency ICU data and longitudinal member claims, including multi-headed transformers.

Hybrid digital twins

Virtual cohorts that simulate treatment policies and trial outcomes, to reduce R&D and trial costs.

Privacy first

Designed for HIPAA and clinical data integrity, with synthetic data for development.
Research
From our research lab · Simulate + Verify + Explain

ICU policy counterfactual simulator

A working research prototype built on 6,460 ICU sepsis stays from MIMIC-IV, recorded in 8-hour steps. Clinicians describe a patient or a cohort and write a treatment policy in plain English. Minutes later, they see what the model expects under that policy compared with the same patients with the drug withheld, next to the trials that tested something similar.

Digital twins and cohorts

Find patients like a trial patient, or define a cohort by immune state, comorbidities, lactate and MAP.

Trial-style comparison

The policy vs. the same patients with the drug withheld, from the same starting point and random draws.

Doubly robust check

AIPW estimates with a positivity verdict that says when the data can't answer.

Robustness

Every apparent benefit is rerun with a second model variant.

Evidence

A 17-study library (ADRENAL, APROCCHSS, CENSER, NICE-SUGAR and more), each with a PubMed link.

Analyst agent

A local LLM writes causal insights from facts computed in code; a clinician manual shows how to review them.

What it found, honestly

Model estimates on retrospective data, not clinical recommendations.

  • Early antibiotics: benefit in both models, confirmed by the doubly robust estimate.
  • Hydrocortisone for refractory shock in hyperinflammatory patients: the first steroid policy both models agree on. It mirrors how ADRENAL and APROCCHSS enrolled, but needs prospective confirmation.
  • Vasopressors: the model reads them as harmful, a known confounding-by-indication bias. The positivity check flags it, so it is not reported as a finding.
Policy vs. the same patients, drug withheldCohort of ICU patientsimmune state · comorbidities · lactate · MAPTreatment policywritten in plain EnglishDigital twin, drug withheldsame start, same random drawsAIPW doubly robust checkpositivity verdict · second model variantEvidence library17-study library · PubMed links
Case Studies

Providers, payers and research partners

Result

PeaceHealth & NIH

Daily steps rose from about 3,000 to 8,500 in a randomized trial; 40+ papers published.

3k → 8.5kdaily steps; 40+ peer-reviewed papers

Challenge

Use social networks to spread healthy behaviours.

Approach

A personal health social network with wearables. Deep learning on sensor and social data, and causal models of how behaviours spread through the social graph.

Result

Statistically significant weight loss in an RCT, and daily activity rising from about 3,000 to 8,500 steps.

Delivered

Humana

Deployed in operations for millions of members; a ComputerWorld best-of-breed award.

Millionsof members; ComputerWorld best-of-breed award

Challenge

Move millions of members from reactive care to proactive, integrated health management.

Approach

An integrated health management platform with time-series feature engineering and deep learning to flag high-risk transitions, and causal models to choose the care interventions with the best long-term outcomes.

Result

Deployed in operations.

In progress

Mcure Biosciences

Mcure Biosciences logo

A hybrid ICU digital twin for an upcoming clinical trial.

Digital twinof the ICU patient environment

Challenge

High-stakes ICU treatment pathways, with fragmented real-world evidence.

Approach

A hybrid digital twin using multi-headed transformers, time-series clustering and hidden Markov models to account for patient heterogeneity. Causal AI estimates direct intervention effects and simulates counterfactual treatments.

Status

Working with Mcure's clinical and data scientists to deploy digital twins in an upcoming trial.

Simulate your next trial before you run it

Bring a population and a treatment question. We'll show what the digital twins and the evidence say.

Book a working session